RX-1 is an orally available small molecule with unique anti-diabetic properties.

The chemical structure and the functional characteristics of RX-1 indicate its anti-diabetic activity is mediated via a novel mode of action.

RX-1 has been tested in a number of (sub)chronic in vivo studies in rodents and monkeys showing significantly improved glucose tolerance, reduced HbA1c levels and lowered fasting plasma glucose levels. Analyses of pancreata from RX-1 treated rats and monkeys indicate that RX-1 increases the fraction of small islets relative to large islets, which is suggestive of neoformation of insulin secreting β-cells.

Our toxicity data obtained in rats and monkeys further support that RX-1 has a very attractive safety profile. RX-1 and analogues thereof are protected by strong intellectual property rights.